Psychotherapy Generally Considered as a First Choice of Panic Attack Treatment
Panic attacks are associated with sudden episodes, of emotions of fear and anxiety. It is a type of anxiety disorder, and other anxiety disorder includes generalized anxiety disorder, obsessive-compulsive disorder (OCD), Posttraumatic stress disorder (PTSD), social anxiety disorder, and special phobias.Generally, panic attacks are not life threatening but they can be frightening and significantly affect the quality of life. Symptoms of the panic attack may vary from person to person, and intensity of attack. In general, symptomsincludes sense of danger, intense fear of loss of control or death, hot flashes, chills, chest pain, sweating, and feeling of detachment. Major risk factors for panic attacks are genetics, major stress due to changes in a life, or traumatic event, and certain changes in brain functioning. According to World Health Organization (WHO), females are at higher risk of panic attacks than males. Panic attacks left untreated, further may link to the depression, anxiety disorders, and psychiatric disorder, suicidal thoughts, and substance abuse. Treatment can help to reduce frequency, and intensity of panic attacks to improve the quality of life. Treatment recommended for panic attacks include psychotherapy (talk therapy), and medications. Psychotherapy generally considered as a first choice of the treatment.
Besides the growing prevalence of stressful living, the market also has a strong pipeline, which is aiding its growth. The Anxiety and Depression Association of America, considers anxiety disorders one of the most common illnesses in the U.S. affecting a sizeable 11% of its population. Additionally, over 2.7% of the U.S. population or roughly 6 million people in the country face anxiety issues triggered by panic attacks.
Despite such high incidence of anxiety, which ideally should have provided the market with momentum, poor diagnosis rate is impeding its trajectory. Besides this, concerns regarding the side effects of medications such as dry mouth, nausea, and habit forming nation could hinder the market’s growth to an extent. However, the capitalizing on untapped opportunities in emerging economies could help companies mitigate these challenges.
Download Important Notes Regarding Panic Attack Treatment: goo.gl/O0bx8D
For the purpose of the study, the global panic attack treatment market can be segmented based on geography, drug, and class. By drug class, the market is segmented into serotonin norepinephrine reuptake inhibitor (SNRI), selective serotonin reuptake inhibitor (SSRI), and benzodiazepines (BZD). Of these, SNRI and SSRI are considered as the first line therapy to be administered to panic attack patients, hence they exhibit clear dominance in the global panic attack treatment market.
The regional segments of the market comprise Europe, Asia Pacific, Latin America, North America, the Middle East and Africa, and Rest of the World. Among these regions, North America emerged dominant in the global market due to the rising incidence of panic attacks witnessed in the region. The high awareness among people related to anxiety disorders and the potential treatment also supports the market’s growth in North America. However, TMR projects the Asia Pacific market to report faster growth during the forecast period.
Some of the key players operating in the global panic attack treatment market are Actavis Pharmaceutical Company, Abbott Laboratories, Bristol-Myers Squibb, Baxter International, GlaxoSmithKline Pharmaceuticals Limited, Eli Lilly and Company, Pfizer,Inc., F. Hoffmann-La Roche, Sumitomo Dainippon Pharma, Noven Pharmaceuticals, Inc., Shionogi and Company, and Recordati Rare Diseases.